Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4711813 | 0.77 | — | — | |
| SCHEMBL2543887 | 0.77 | — | — | |
| SCHEMBL3750095 | 0.76 | USP2 (0.38) | MAPTUSP2KMT2AALDH1A1LMNA | |
| SCHEMBL28621500 | 0.76 | USP2 (0.38) | MAPTUSP2KMT2AALDH1A1LMNA | |
| SCHEMBL2547791 | 0.75 | FDPS (0.41) | MAPTKMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6476772 | 0.73 | USP2 (0.35) | MAPTUSP2KMT2AALDH1A1LMNA | |
| SCHEMBL18922366 | 0.73 | SMN1; SMN2 (0.35) | MAPTUSP2KMT2AALDH1A1LMNA | |
| SCHEMBL6476776 | 0.73 | USP2 (0.35) | MAPTUSP2KMT2AALDH1A1LMNA | |
| SCHEMBL16584000 | 0.72 | — | — | |
| SCHEMBL5077735 | 0.71 | MAPT (0.39) | MAPTKMT2AALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | claimed |
| EP-1656350-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | claimed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | claimed |
| WO-2005005394-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | claimed |
| US-5736548-A | CYCLIC GUANOSINE 3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; TREATING HEART FAILURE, HYPERTENSION | SANOFI (FR) | 1998-04-07 | — | — | US | claimed |
| WO-2015097123-A1 | NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-07-02 | — | — | WO | disclosed |
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1656350-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | disclosed |
| WO-2005005394-A2 | THIOPHENYLAMINOIMIDAZOLINES AS PROSTAGLANDIN I2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-01-20 | — | — | WO | disclosed |
| US-5958929-A | CONGESTIVE HEART FAILURE; HYPOTENSIVE AGENTS | SANOFI (FR) | 1999-09-28 | — | — | US | disclosed |
| EP-0802904-B1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AG (DE) | 1998-09-09 | — | — | EP | disclosed |
| US-5736548-A | CYCLIC GUANOSINE 3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS; TREATING HEART FAILURE, HYPERTENSION | SANOFI (FR) | 1998-04-07 | — | — | US | disclosed |
| WO-1996028448-A1 | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996021647-A1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | TBXA2R, MRGPRX2, MRGPRX1 | MAPT 4692/4885USP2 4603/4885KMT2A 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.